Cencora, Inc. (NYSE:COR) Receives $259.44 Average Price Target from Analysts

Cencora, Inc. (NYSE:COR) has been given a consensus rating of “Moderate Buy” by the ten brokerages that are presently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $259.44.

COR has been the topic of a number of research analyst reports. Robert W. Baird lowered their price target on Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a report on Friday, September 6th. StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Bank of America reaffirmed a “neutral” rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Evercore ISI cut their target price on shares of Cencora from $270.00 to $250.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Finally, JPMorgan Chase & Co. increased their price objective on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a report on Wednesday, August 21st.

Insider Activity at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 15.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cencora

A number of hedge funds have recently bought and sold shares of COR. Price T Rowe Associates Inc. MD acquired a new position in shares of Cencora during the 1st quarter worth about $2,183,619,000. JPMorgan Chase & Co. bought a new stake in shares of Cencora in the first quarter valued at approximately $1,199,695,000. Boston Partners acquired a new stake in shares of Cencora in the first quarter worth $1,001,269,000. Capital Research Global Investors bought a new position in Cencora during the first quarter worth $650,424,000. Finally, Bessemer Group Inc. acquired a new position in Cencora during the 1st quarter valued at $556,245,000. 97.52% of the stock is currently owned by institutional investors.

Cencora Trading Up 4.9 %

Shares of NYSE COR opened at $245.38 on Thursday. The business has a fifty day simple moving average of $231.57 and a 200-day simple moving average of $230.64. The company has a market cap of $48.35 billion, a price-to-earnings ratio of 26.64, a P/E/G ratio of 1.49 and a beta of 0.44. Cencora has a 12 month low of $191.11 and a 12 month high of $247.66. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.